A body of British citizen scientists, medical clinicians, academics, manufacturers and engineers has developed an alternative model of ventilator to support the Government’s drive to equip the NHS.
British taskforce reinvents trusted technology to help solve NHS crisis
The new model, the exovent, is a cutting-edge reinvention of the archetypal iron lung which saved the lives of countless polio victims during the last century.
Marshall Aerospace & Defence Group, the UK’s leading privately owned Aerospace and Defence business, is exploring the technical aspects of the scheme ahead of rapid production and roll-out of the Negative Pressure Ventilator (NPV). The exovent concept is also supported by WMG at the University of Warwick and representatives from Imperial NHS Trust and The Royal National Throat Nose and Ear hospital. Two leading intensive care units have agreed to trial the prototype ventilator support devices.
With only a small number of moving parts, the components are readily available now in the UK and are not required by other manufacturers currently commissioned by the Government to build conventional Intermittent Positive Pressure Ventilators (IPPV). More types of ventilator can then be built simultaneously – with the aim of 5000 exovents a week being produced – and more options can be provided to clinicians choosing the most appropriate device for each patient.
exovent is non-invasive, which means that patients do not need to have their windpipes intubated, so they don’t need to be sedated or paralysed. Instead, they can remain conscious, take medication and nutrition by mouth, and talk to loved ones on the phone. It can be used on a normal ward, keeping patients out of intensive care.
The device works by being fitted over the patient’s torso and taking over their breathing through gentle and repeating pressure. It increases the heart’s efficiency by up to 25% compared to conventional ventilators which squeeze the chest and may actually reduce cardiac function.
The ventilation support device is supported by Sir John Burn, professor of Clinical Genetics at Newcastle University, who is leading the development of a Covid-19 antigen test:
“The exovent team has cleverly adapted the old concept of the iron lung which was used for treating polio. This device is cheap, simple and it will work. I am convinced it provides a real alternative and is worthy of support.”
Speaking on the concept, the task force's leading clinician Dr Malcolm Coulthard said: "The team has been working flat out for the last 10 days. We started out looking at negative pressure ventilator technology thinking that it would allow us to produce literally thousands of ventilators very quickly and cheaply to cope with the tsunami of people with pneumonia that may be upon us because of the Covid-19 virus.
“However, as soon as we looked into the science and the literature it immediately became apparent that this will allow us to produce less-invasive devices than the conventional units in current use, possibly better for patients’ hearts, at a fraction of the price, using off-the-shelf parts.
“exovent can provide an alternative choice to using Continuous Positive Airways Pressure (CPAP) by delivering continuous Negative End Expiratory Pressure (NEEP). This method does not require to be driven by pressurised air or oxygen, and additional oxygen that the patient needs can be provided with tubing or a face mask as required.”
Margot James, Executive Chair, WMG University of Warwick said: “We are delighted to be working with exovent to help scale up their non-invasive ventilator from prototype to volume manufacturing. Our engineers and researchers are collaborating with the exovent team on the design, engineering, component sourcing and assembly of the ventilator. I am extremely proud of the unstinting and dedicated efforts of our research team, led by Archie MacPherson at WMG, and glad that we are able to apply our expertise to this important project.”
The family of Stephen Hawking said: “As the family of a ventilated man, we know the life and death difference that access to this kind of medical technology makes. The COVID 19 epidemic has caused worldwide demand for ventilators vastly to outstrip supply. We are so proud to support the technological and manufacturing innovation involved in producing low cost, effective ventilators swiftly and in large numbers and hope the combined efforts of everyone who has answered this call will mean the NHS receives the equipment it needs to save lives at this terrible time.”
Images - credit: John Hunter, Steer Energy
Founded in 1909, the Marshall Group has a turnover of £2.5bn and over 5,700 employees. Headquartered on a 900-acre site in Cambridge, Marshall has three principal arms to the business: Aerospace and Defence; Property; and Ventures.